Deschloroketamine (DCK/DXE): Complete Toxicology, Dependence & Safety Monograph

Deschloroketamine (DCK/DXE): Complete Toxicology, Dependence & Safety Monograph

Emergency dissociative toxicity: Severe unresponsiveness, abnormal breathing, seizure, collapse, dangerous agitation/confusion, chest pain, serious injury, or persistent vomiting with reduced consciousness after an unknown dissociative requires urgent medical care.

Quick answer

Deschloroketamine (DCK, DXE, 2-oxo-PCM) is a ketamine-related dissociative that blocks NMDA receptors.

It is chemically distinct from:

• ketamine;
• 2F-DCK;
• O-PCE;
• DMXE;
• PCP/PCE analogues.

Its evidence base is asymmetric:

• NMDA pharmacology: directly studied;
• drug-market presence: analytically confirmed;
• forensic detection: documented;
• human standalone clinical toxicity: sparse;
• human PK: not established;
• dependence/withdrawal incidence: not established.

That asymmetry should stay visible.

Identity

History and emergence

DCK existed as a chemical entity long before its modern recreational market.

Forensic laboratories began characterizing it as a designer drug in the mid-2010s. A 2016 analytical paper documented DCK in seized powder and established reference mass-spectrometric/NMR data.

By the late 2010s and early 2020s, DCK increasingly appeared alongside other ketamine analogues in:

• urine toxicology;
• blood and hair;
• online research-chemical markets;
• mixed dissociative exposures.

The modern market is therefore not a single “DCK era,” but part of a rapid substitution cycle involving 2F-DCK, O-PCE, FXE and other arylcyclohexylamines.

Pharmacology

NMDA receptor antagonism

A 2021 study directly measured DCK activity at human NMDA receptors and found antagonist activity comparable to ketamine in the experimental system.

S-DCK was generally more active than R-DCK.

In rats, DCK:

• rapidly entered the brain;
• produced locomotor stimulation;
• disrupted prepulse inhibition;
• produced conditioned place preference.

The study supports both dissociative pharmacology and abuse liability.

What the rat study cannot tell us

It does not establish:

• a human dose;
• a ketamine-equivalent conversion;
• a human half-life;
• a human toxic threshold;
• a safe redosing interval.

“Comparable NMDA activity” is not “clinically interchangeable.”

Human evidence

Mixed ketamine-analogue clinical cases

In a 2020 Hong Kong cluster of 20 analytically confirmed 2F-DCK exposures, DCK was also detected in 50% of cases.

Clinical findings across the cluster included:

• impaired consciousness;
• agitation;
• abnormal behavior;
• hypertension;
• tachycardia;
• loss of consciousness or convulsion in some patients.

Because nearly every patient had multiple ketamine-type drugs detected, those clinical effects cannot be assigned cleanly to DCK alone.

French addictovigilance

A 2026 French analysis of ketamine analogues included DCK among substances of interest.

Across 56 ketamine-analogue cases from 2017–2024, serious outcomes were common and deaths occurred, with neurological/psychiatric effects predominating.

The report is valuable family-level human evidence, but it does not provide a DCK-only toxicity curve.

Fatal and forensic evidence

DCK has been identified in postmortem biological samples and hair.

A 2021 forensic paper identified DCK, 2F-DCK and MXPr in a death by fall, demonstrating the complexity of attributing causality when multiple dissociatives are present.

A 2024 paper involving 2F-DCK-related deaths also detected DCK.

DCK can be exposure—or a metabolite signal

The 2024 study raises an important forensic issue:

• in one case, DCK powder was found at the scene, supporting direct DCK use;
• in another, DCK may have arisen from 2F-DCK metabolism.

Therefore:

A DCK-positive toxicology result does not always prove intentional standalone DCK administration.

Analytical and scene context matter.

Metabolism

DCK-related metabolism studies support pathways involving:

• N-dealkylation;
• hydroxylation;
• further oxidation;
• conjugation.

The exact human metabolic map is less mature than ketamine's.

Modern LC-HRMS approaches can identify parent DCK and metabolites in blood, urine or hair.

Pharmacokinetics

Preclinical evidence

The 2021 rat study found rapid brain penetration and a somewhat slower PK profile than ketamine in that model.

Human evidence

Controlled human DCK pharmacokinetic studies have not established:

• oral/intranasal/inhaled bioavailability;
• time to peak concentration;
• half-life;
• clearance;
• repeated-use accumulation;
• active-metabolite contribution.

A forum duration estimate is not a human PK study.

Acute toxicity

Likely and observed dissociative-class effects include:

• impaired consciousness;
• disorientation;
• agitation;
• abnormal behavior;
• hypertension;
• tachycardia;
• impaired coordination;
• vomiting/aspiration risk;
• convulsion in mixed ketamine-analogue cases.

Severe injury can occur indirectly through:

• falls;
• traffic events;
• drowning;
• exposure to unsafe environments while dissociated.

Respiratory effects

Ketamine-like dissociatives typically differ from potent opioids in respiratory pharmacology, but severe mixed exposures can still involve:

• reduced consciousness;
• airway obstruction;
• aspiration;
• respiratory compromise from co-drugs.

An unknown powder can also contain substances outside the expected dissociative class.

Interactions

No controlled DCK interaction program exists.

Important concerns include:

• alcohol and sedatives → more impaired consciousness/aspiration risk;
• opioids → respiratory-depression risk from the opioid component;
• other dissociatives → unpredictable depth/duration;
• stimulants → greater cardiovascular/behavioral stress.

There is no evidence-based DCK combination table that proves safety.

Tolerance

Repeated NMDA-antagonist exposure can produce tolerance to dissociative effects.

DCK-specific human tolerance studies are absent.

A person feeling less dissociated after repeated use does not prove equivalent tolerance to:

• impaired coordination;
• hypertension;
• cognitive effects;
• organ toxicity;
• accident risk.

Physical dependence and problematic use

The DCK rat study found conditioned place preference, supporting abuse liability.

Human epidemiology does not establish a DCK-specific dependence rate.

Regular-use profiles in broader ketamine-analogue surveillance show that repeated dissociative use can become problematic, but DCK should not simply inherit ketamine's exact dependence statistics.

Withdrawal

There is no validated DCK-specific withdrawal syndrome or timeline.

With frequent ketamine-class use, people can report:

• craving;
• low mood;
• anxiety;
• sleep disturbance;
• irritability;
• difficulty stopping.

Those are clinically relevant, but a DCK-specific onset/peak/duration curve has not been established.

Treatment and support

There is no medication approved specifically for DCK use disorder.

Care is generally based on:

• supportive management of acute dissociative intoxication;
• treatment of injuries/medical complications;
• assessment for substance use disorder;
• behavioral treatment for problematic dissociative use;
• management of co-occurring psychiatric/substance conditions.

U.S. treatment resources include FindTreatment.gov and SAMHSA's National Helpline at 1-800-662-HELP (4357).

Bladder and urinary toxicity: class concern, not quantified DCK fact

Chronic ketamine exposure can cause severe ketamine-associated cystitis and urinary-tract injury.

DCK-specific prospective bladder studies are not available.

Because DCK is structurally/pharmacologically related, urinary toxicity is a reasonable class-level concern that deserves monitoring, but the site should not claim a known DCK incidence or threshold.

Persistent urinary pain, frequency, urgency or blood in urine warrants medical evaluation.

Cognitive and psychiatric concerns

Long-term DCK-specific studies are absent.

Ketamine-class concerns include:

• cognitive impairment with heavy repeated use;
• dissociation-related functional impairment;
• mood/psychiatric destabilization in susceptible people.

The magnitude of those risks for DCK is unknown.

Drug testing

Routine immunoassays

Routine hospital/workplace panels should not be assumed to detect DCK.

A ketamine assay does not automatically include DCK.

Definitive testing

Analytical methods include:

• LC-MS/MS;
• LC-HRMS;
• validated urine panels;
• blood/hair analysis.

Reference standards and updated libraries matter because arylcyclohexylamine markets evolve quickly.

Forensic interpretation

Parent DCK does not automatically identify source

DCK may reflect:

• direct DCK use;
• mixed product exposure;
• in some contexts, 2F-DCK metabolism.

Concentration is not a human dose chart

Forensic concentration depends on:

• timing;
• specimen;
• metabolism;
• co-drugs;
• tolerance;
• postmortem changes.

No validated DCK fatal blood threshold exists.

Detection is not sole causation

A DCK-positive death with other dissociatives or psychoactive drugs requires case-specific attribution.

Product identity and substitution risk

Research-chemical products may be:

• mislabeled;
• substituted;
• mixtures of ketamine analogues;
• different from a prior batch.

The Hong Kong cluster showing multiple ketamine-type drugs in the same patients illustrates this problem directly.

Special populations

Controlled DCK data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• severe psychiatric illness;
• liver/kidney disease;
• urinary-tract disease.

Missing evidence should not be treated as safety.

Legal status — dated October 2, 2026

DCK must be distinguished from 2F-DCK.

DEA issued a separate temporary Schedule I action for 2F-DCK in May 2026. That action does not make the two molecules identical.

This review did not identify a primary federal action specifically naming DCK in the current DEA scheduling material cited here. Federal analogue law or state-specific controls may still apply depending on facts and jurisdiction.

Therefore the responsible legal summary is:

Do not infer DCK's status from ketamine or 2F-DCK. Check the exact molecule, jurisdiction and date.

This is general regulatory information, not individualized legal advice.

Myths and misconceptions

“DCK is just longer-lasting ketamine.”
Too simplistic. It is a distinct molecule with separate PK and human-data gaps.

“Comparable NMDA potency means equal human doses.”
False.

“If DCK is found in blood, the person definitely took DCK directly.”
Not always; 2F-DCK metabolism can complicate interpretation.

“Ketamine urine tests automatically detect DCK.”
Not reliably.

“Ketamine bladder damage proves the exact DCK risk.”
No. It creates a class-level concern, not a DCK incidence estimate.

“Tolerance makes repeated use safer.”
No. Subjective tolerance does not guarantee protection from accidents, organ effects or cognitive impairment.

Evidence ledger

Related evidence

• 2F-DCK
• O-PCE
• DMXE
• 3-MeO-PCE
• 3-HO-PCP
• FXE
• RC dissociatives evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

DCK has enough evidence to be treated as a real dissociative drug—not a forum-only research chemical—but far less human evidence than ketamine.

The most important scientific boundaries are:

• DCK is a genuine NMDA antagonist;
• human standalone toxicity and PK remain poorly characterized;
• mixed ketamine-analogue exposure is common;
• DCK can complicate forensic interpretation because it may sometimes appear after 2F-DCK exposure;
• ketamine-class chronic harms are relevant warnings, not DCK-specific incidence estimates.

That makes a careful uncertainty map more useful than a dose chart.